补金片联合抗痨药物治疗结核性渗出性胸膜炎的临床研究  

COMBNATION OF BUJINPIAN AND ANTIPHTHISIC DRUGS IN TREATING TUBERCULOUS EXUDATIVE PLEURISY

作　　者：梁红文 苏明 杨贵发 

机构地区：[1]临沂市胸科医院,山东临沂276001

出　　处：《山东医学高等专科学校学报》2006年第1期39-41,共3页Journal of Shandong Medical College

基　　金：临沂市科技发展计划项目(No.0508075)

摘　　要：目的观察补金片治疗结核性渗出性胸膜炎的临床疗效。方法将76例患者随机分为2组,对照组常规应用异烟肼(INH)、利福平(RFP)、吡嗪酰胺(PZA)、链霉素(Sm)抗痨治疗;治疗组应用补金片联合上述药物抗痨治疗,两周为1疗程,连续治疗3个疗程。结果治疗第6周末改善临床症状与促进胸水吸收的总有效率,治疗组分别是97.36%和94.73%,对照组分别是84.21%和81.57%;两组比较均有显著性差异(P<0.05);胸膜肥厚与粘连的发生率,治疗组分别是23.68%和7.89%,对照组分别是44.74%和18.42%,两组比较,均有显著性差异(P<0.05)。结论补金片在改善临床症状、促进胸水吸收、防止胸膜肥厚粘连以及防止肝脏损害方面有较好疗效,值得临床推广应用。Objective To explore the curative effects of Bujinpian, a traditional Chinese medicine, on tuberculous exudative pleurisy. Methods 76 cases were randomly divided into two groups. The contrast group received antiphthisic treatment with isonicotinylhydrazide（INH）, rifarnpicin（RFP）, pyrazinarnide（PZA） and streptomycin（SM）, while the treatment groups was treated with Bujinpian as well as the above mentioned antiphthisic therapy, two weeks as a course of treatment. The patients in both groups received three courses of treatment. Results The total effects of improving clinical symptoms and absorbing hydrothorax were 97.36 % and 94.73 % in the treatment group and 84.21% and 81.57% in the contrast group respectively. The incidences of pleural thickening and conglutination were 23.68% and 7.89% in the treatment group and 44.74% and 18.42% in the contrast group respectively, There existed significant differences between the groups （ P 〈 0.01 ）. Conclu- sion Bujinpian can be used to improve clinical symptoms, promote the absorption of hydrothorax, prevent pldural thickening and conglutination and protect liver effectively, therefore, it deserves to be widely applied clinically.

关 键 词：补金片 结核性胸膜炎 

分 类 号：R521.7[医药卫生—内科学]